Introduction
Acute myeloid leukemia (AML) is an aggressive hematological disease that is characterized by the overproduction of early myeloid precursor cells, often to the exclusion of other cell lines. It leads to anemia, thrombocytopenia, and neutropenia, 1,2 all of which typically have poor outcomes. Recently, some significant improvements have been achieved in our understanding of AML biology and genetics. These fundamental discoveries are now being translated into new diagnostic and therapeutic strategies for this disease. methylation in AML patients with DNMT3A mutations, and this hypomethylation correlated with higher relapse rates and poorer overall survival (OS). 6 Many recent studies have also suggested that the DNMT3A mutation should be considered a poor prognostic factor in AML. [5] [6] [7] [8] [9] The frequencies of IDH1 and IDH2 mutations in AML are approximately 6-16% and 8-19%, respectively. 10, 11 IDH is an essential metabolic enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-KG. The IDH1/2 gene mutations give rise to reduced levels of α-KG and increased levels of 2HG. 10, 12 In AML, increasing cellular 2HG levels will inhibit α-KG-dependent enzymes that are important for the demethylation of DNA. 10, 13, 14 Studies have shown that IDH1/2 mut display global DNA hypermethylation, and in hematopoietic stem cells, expression of mutant IDH1/2 increases the expression of stem cell markers and impaired myeloid differentiation. 15 A recent meta-analysis indicated that IDH1 mutations confer a poorer OS and event-free survival (EFS). However, for IDH2, some differences were noted. The IDH2 R140 mutations were associated with better OS among younger cases, whereas outcome was poor for patients with the IDH2 R172 mutation. 10, 16 Mutations in DNMT3A and IDH1/2 have a significant effect on the prognosis of AML patients. They are both involved in the epigenetic regulation of transcription, particularly, alterations in DNA methylation. In addition, these genes both show a high co-mutation rate. However, whether the pattern of association between DNMT3A mut and IDH1/2 mut suggests an interplay in the prognosis of AML remains unknown. This study aims to determine whether IDH1/2 influences the outcomes of AML patients with the DNMT3A mutation, and its effects.
Patients and methods Patients
Fifty-one patients diagnosed with AML and the DNMT3A mutation were enrolled in the study. To further support the analysis, we used the data of patients in the Clinseq cohort. 18 There were 63 patients with the DNMT3A mutation in the Clinseq cohort who were diagnosed between February 1997 and August 2014. Bone marrow or peripheral blood samples were obtained at the time of diagnosis. These patients were treated with intensive induction regimens, including anthracyclines and cytosine arabinoside, according to national guidelines. 19 
Statistical analysis
The primary study endpoints were EFS and OS. The EFS was defined as that time from the date of diagnosis to removal from the study, owing to the absence of complete remission, relapse, or death. The OS was defined as that time from the date of diagnosis to death by any cause. For patients in the Clinseq cohort, we considered OS as the primary outcome.
The demographics and characteristics of the subjects were summarized using descriptive statistics. Intergroup difference was performed using the Student's t-test and chi-square test. Survival analyses were performed using the Kaplan-Meier method. A two-sided P-value <0.05 was considered statistically significant. All statistical analyses were performed with the SPSS software 20.0 (IBM Corporation, Armonk, NY, USA).
Results

Demographic and biological characteristics
The mutation rates of IDH are shown in Figure 1 . Sixteen patients had either the IDH1 or IDH2 mutation, accounting for 31.4%. The IDH1 mutations were observed more frequently than IDH2 mutations. Eleven patients with the IDH1 mutation had a mutation at R132. Three patients with the IDH2-mutation had an IDH2 R140 mutation, and the other 2 had an IDH2 R172 mutation. The demographic and biological characteristics and the intergroup differences are summarized in In order to determine which patients were more likely to be affected by the IDH1/2 mutation, we stratified the data by several aspects, such as age, WBC count, percentages of BM blasts and PB blasts, mutated recurrent gene numbers, and frequently mutated genes, such as FLT3 and NPM1.
The results of the Kaplan-Meier analysis for EFS and OS are summarized in Table 2 . Although the median survival time seemed longer in the double mutation group in several aspects, such as age <60 years, BM blasts or PB blasts <70%, FLT3 mutation absent, and NPM1 mutation present, no significant differences were observed among any of these characteristics (P> 0.05).
In the entire cohort, no signif icant differences were observed in EFS or OS of patients between the DNMT3A mut IDH1/2 wild and DNMT3A mut IDH1/2 mut groups ( Figure 2A and B, P> 0.05). We divided the patients into 2 groups according to treatment, and observed no significant differences in either group ( Figure 2C -F, P> 0.05). The HSCT showed better efficacy than chemotherapy in the DNMT3A mut IDH1/2 wild group, and led to a higher EFS and OS ( Figure 3A and B, P=0.010 for EFS and P=0.007 for OS). However, in the DNMT3A mut IDH1/2 mut group, no significant differences were observed between the two treatment methods ( Figure 3C and D, P> 0.05).
Considering the differences in effect of IDH1 and IDH2 mutations on the prognosis of patients, we divided the entire cohort into 3 groups, more specifically the chi-square test. Abbreviations: AML FAB, the French-American-British classification of acute myeloid leukemia; WBC, white blood cell; BM, bone marrow; PB, peripheral blood; ITD, internal tandem duplication; TKD, tyrosine kinase domain; HSCT, hematopoietic stem cell transplantation; Allo-HSCT, allogeneic-hematopoietic stem cell transplantation; Auto-HSCT, autogenic-hematopoietic stem cell transplantation; mut, mutation; wild, wild type. Figure 5A, P=0.128 ). In Figure 5B , patients with the IDH2 R140 mutation were considered a single group. Furthermore, because of their relatively consistent effects on the prognosis, patients with mutations Figure 2 Kaplan-Meier analysis of EFS and OS. Notes: (A,B) IDH1/2 mutation status had no effect on EFS or OS in the whole cohort. (C,D) IDH1/2 mutation status had no effect on EFS or OS for the patients subjected to chemotherapy. (E,F) IDH1/2 mutation status had no effect on EFS or OS for the patients subjected to HSCT. Abbreviations: EFS, event-free survival; OS, overall survival; HSCT, hematopoietic stem cell transplantation. 
2463
Clinical and biological implications of IDH1/2 in DNMT3A-mutated AML of IDH1 and IDH2 R172 were divided into 2 groups. No significant differences were observed in the OS among these 3 groups (P=0.124).
Discussion
We synthetically analyzed different aspects of the effects of IDH1/2 mut on the outcomes of patients with DNMT3A-mutated AML; however, no significant differences were found. The HSCT could be a more favorable option for patients with the DNMT3A mutation. However, HSCT and chemotherapy showed no significant differences in patients with double mutations. The DNMT3A mut IDH1/2 mut group showed relatively lower rates of NPM1 mutation.
Previous studies have indicated that NPM1 and doublemutated CEBPA have positive effects, whereas FLT3-ITD, TET2, KRAS, PTPN11, U2AF1, and MLL-PTD mutations have adverse effects on the outcomes of AML patients. [20] [21] [22] [23] [24] [25] [26] [27] Mutations of SMC3, RAD21, and NRAS were thought to have little to no influence on those studies, whereas the effects of other gene mutations, such as that of SMC1A, on the prognosis of AML had not been clearly determined. [20] [21] [22] [23] [24] [25] [26] [27] In our cohort, 54.9% of the patients had NPM1 mutations. Patients in the DNMT3A mut IDH1/2 mut group had a lower mutation rate of NPM1 (45.1% versus 9.8%). In another study, about 80% of DNMT3A-mutated patients had NPM1 mutations, and 65.4% of the double-mutation patients concurrently harbored NPM1 mutations. 8 Rakheja et al indicated that IDH1 R132 and IDH2 R140 mutations are frequently accompanied by NPM1 mutations in AML. 10 In our cohort, 87.5% of the patients harbored IDH1 R132 or IDH2
R140
; however, we observed no correlation between NPM1 and IDH1/2. The reason for this difference might be due to the age distribution of the sample, the small sample size, or the research background of our cohort.
Many studies have attempted to elucidate the effects of multiple gene mutations on the outcomes of AML. More Notes: (A,B) IDH1 and IDH2 mutation status had no effect on EFS or OS in the whole cohort. (C,D) IDH1 and IDH2 mutation status had no effect on EFS or OS for patients subjected to HSCT. Abbreviations: EFS, event-free survival; OS, overall survival; HSCT, hematopoietic stem cell transplantation.
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Clinical and biological implications of IDH1/2 in DNMT3A-mutated AML specifically, studies have shown that FLT3-ITD with the DNMT3A R882 double mutation is a poor prognostic factor in AML; 28 whereas NPM1 mutations do not seem to have a significant effect on the outcomes of patients with DNMT3A-mutated AML. 8 Alternatively, IDH1/2 mut constitute a poor prognostic factor in NPM1-mutated cytogenetically normal-AML (CN-AML) without FLT3-ITD. 29 Our study revealed that IDH1/2 mut have little influence on the outcomes of patients with DNMT3A-mutated AML.
The HSCT has been confirmed as an effective therapy for intermediate-or high-risk patients with AML. Patients at higher risk usually benefit more from transplant therapy. The survival of CN-AML patients with DNMT3A mut could be improved following allo-HSCT. 30 Nevertheless, as we have mentioned before, the FLT3-ITD and DNMT3A R882 double mutation is a poor prognostic factor in AML. Patients with this condition have significantly lower 2-year OS and leukemia-free survival (the duration from post-transplantation to recurrence of leukemia or death) following allo-HSCT, than patients with single FLT3-ITD or DNMT3A mut . 28 In comparison with chemotherapy, our results demonstrate that HSCT had a more favorable therapeutic effect on patients with the DNMT3A mutation. When IDH1/2 mut were taken into account however, the effects of these two therapies were statistically equivalent. Patients with the DNMT3A and IDH1/2 double mutation showed no gain in EFS or OS after either HSCT or chemotherapy. This result suggests that IDH1/2 mut might not be a strong biomarker for HSCT therapy in patients with the DNMT3A mutation. Analysis of data from the Clinseq cohort further supported the view that IDH1/2 mut in patients with AML who received chemotherapy had little effect on the outcomes of those with the DNMT3A mutation. The results of the analysis in which different mutations of IDH were separated also showed that they had no impact on the prognosis of these patients, even though mutations of IDH1, IDH2
R140
, and IDH2 R172 might have different effects on the outcome.
In addition to HSCT, targeted therapy is now one of the more popular treatment choices that can show good efficacy. Enasidenib (AG-221) is a reversible and selective inhibitor of mutant IDH2. 3, 31, 32 Inhibitors of IDH1, such as AG-120 and IDH305, are also under investigation. 3 Although our study showed that IDH1/2 mut have no influence on the outcomes of AML patients with DNMT3A mut , because of the development of novel, effective target drugs, IDH1/2 inhibitors might have positive effects on the overall prognosis of patients with double mutations.
Limitations
Several limitations of the present study need to be acknowledged. Our study is a retrospective study with a relatively small sample size, and some bias needs to be considered. In some groups, the number of samples was less than 5, thus limiting further statistical analysis. Therefore, the present results need to be verified in larger cohorts.
Conclusion
We propose that IDH1/2 has no impact on the prognosis of AML patients with the DNMT3A mutation. Furthermore, HSCT showed a more favorable therapeutic effect for patients with the DNMT3A, but without the IDH1/2 mutation. For patients with double mutations, the efficacy of HSCT was similar to that of chemotherapy.
